

Phil Skolnick

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3663004/publications.pdf>

Version: 2024-02-01

30
papers

2,914
citations

361413

20
h-index

501196

28
g-index

31
all docs

31
docs citations

31
times ranked

3479
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment of overdose in the synthetic opioid era. , 2022, 233, 108019.		49
2	Countermeasures for Preventing and Treating Opioid Overdose. Clinical Pharmacology and Therapeutics, 2021, 109, 578-590.	4.7	38
3	Cannabinoid1 (CB-1) receptor antagonists: a molecular approach to treating acute cannabinoid overdose. Journal of Neural Transmission, 2020, 127, 279-286.	2.8	2
4	Enhanced Intranasal Absorption of Naltrexone by Dodecyl Maltopyranoside: Implications for the Treatment of Opioid Overdose. Journal of Clinical Pharmacology, 2019, 59, 947-957.	2.0	14
5	Pharmacokinetic Interaction between Naloxone and Naltrexone Following Intranasal Administration to Healthy Subjects. Drug Metabolism and Disposition, 2019, 47, 690-698.	3.3	8
6	Fighting Fire with Fire: Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose. Journal of Pharmacology and Experimental Therapeutics, 2019, 371, 409-415.	2.5	40
7	Be positive about negativesâ€“recommendations for the publication of negative (or null) results. European Neuropsychopharmacology, 2019, 29, 1312-1320.	0.7	28
8	The development of glutamate-based antidepressants is taking longer than expected. Drug Discovery Today, 2018, 23, 1689-1692.	6.4	12
9	The Opioid Epidemic: Crisis and Solutions. Annual Review of Pharmacology and Toxicology, 2018, 58, 143-159.	9.4	225
10	On the front lines of the opioid epidemic: Rescue by naloxone. European Journal of Pharmacology, 2018, 835, 147-153.	3.5	47
11	From bench to bedside: mGluR2 positive allosteric modulators as medications to treat substance use disorders. Psychopharmacology, 2017, 234, 1347-1355.	3.1	12
12	Pharmacokinetic Properties and Human Use Characteristics of an FDAâ€“Approved Intranasal Naloxone Product for the Treatment of Opioid Overdose. Journal of Clinical Pharmacology, 2016, 56, 1243-1253.	2.0	79
13	Mitigating the Effects of Nonadherence in Clinical Trials. Journal of Clinical Pharmacology, 2016, 56, 1151-1164.	2.0	80
14	Re-energizing the Development of Pain Therapeutics in Light of the Opioid Epidemic. Neuron, 2016, 92, 294-297.	8.1	56
15	Effect of NMDAR antagonists in the tetrabenazine test for antidepressants: comparison with the tail suspension test. Acta Neuropsychiatrica, 2015, 27, 228-234.	2.1	13
16	Outcome Measures in Medication Trials for Substance Use Disorders. Current Treatment Options in Psychiatry, 2015, 2, 113-121.	1.9	17
17	Biologic Approaches to Treat Substance-Use Disorders. Trends in Pharmacological Sciences, 2015, 36, 628-635.	8.7	26
18	Harry L June. Neuropsychopharmacology, 2014, 39, 3135-3135.	5.4	0

#	ARTICLE	IF	CITATIONS
19	Translational potential of naloxone and naltrexone as TLR4 antagonists. Trends in Pharmacological Sciences, 2014, 35, 431-432.	8.7	20
20	Addiction Therapeutics: Obstacles and Opportunities. Biological Psychiatry, 2012, 72, 890-891.	1.3	21
21	Anxiolytic anxiolytics: on a quest for the Holy Grail. Trends in Pharmacological Sciences, 2012, 33, 611-620.	8.7	88
22	Glutamate-based antidepressants: 20 years on. Trends in Pharmacological Sciences, 2009, 30, 563-569.	8.7	370
23	Glutamate and Depression. Annals of the New York Academy of Sciences, 2003, 1003, 250-272.	3.8	375
24	Antidepressant-like actions of an AMPA receptor potentiator (LY392098). Neuropharmacology, 2001, 40, 1028-1033.	4.1	203
25	Intra- and interstrain differences in models of "behavioral despair". Pharmacology Biochemistry and Behavior, 2001, 70, 187-192.	2.9	228
26	Distinct Loci Mediate the Direct and Indirect Actions of the Anesthetic Etomidate at GABA _A Receptors. Journal of Neurochemistry, 1997, 69, 1310-1313.	3.9	40
27	Differences in fear motivated behaviors among inbred mouse strains. Psychopharmacology, 1993, 111, 323-331.	3.1	397
28	.beta.-Carbolines: synthesis and neurochemical and pharmacological actions on brain benzodiazepine receptors. Journal of Medicinal Chemistry, 1982, 25, 1081-1091.	6.4	173
29	The mechanism(s) of action of the benzodiazepines. Medicinal Research Reviews, 1981, 1, 3-22.	10.5	46
30	Demonstration of specific "high affinity" binding sites for [3H] imipramine on human platelets. Life Sciences, 1980, 26, 953-959.	4.3	206